Condition: Advanced Cancer · Sponsor: Riboscience, LLC.
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with other cancer treatments including monotherapy and in combination with other cancer treatments including immunotherapy or chemotherapy. This study is an open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in combination with pembrolizumab or other approved anticancer therapies or as a monotherapy in subjects with advanced unresectable, recurrent or metastatic tumors. The phase 1a (dose escalation phase) has been completed. The Phase 1b expansion phase of the study has been increased in size and scope.
This description comes directly from the study's public registry record.
Riboscience Clinical Trials · (415) 754-3182 · clinicaltrials@riboscience.com
Always discuss trial participation with your own doctor first.
| Honor Health Research Institute | Scottsdale, Arizona, United States | Recruiting |
| University of Arizona | Tucson, Arizona, United States | Recruiting |
| Stanford Cancer Institute | Palo Alto, California, United States | Recruiting |
| UCLA Hematology/Oncology - Santa Monica | Santa Monica, California, United States | Recruiting |
| Christiana Care Health Services | Newark, Delaware, United States | Recruiting |
| Norton Cancer Institute | Louisville, Kentucky, United States | Recruiting |
| Ochsner Clinic Foundation | New Orleans, Louisiana, United States | Recruiting |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| American Oncology Partners of Maryland | Bethesda, Maryland, United States | Recruiting |
| Ichan School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| Carolina BioOncology Institute | Huntersville, North Carolina, United States | Completed |
| Vanderbilt-Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05270213